Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Tarsus Pharmaceuticals Inc.
Headquarters: Irvine, CA, United States of America
Website: https://www.tarsusrx.com
Year Founded: 2017
Status: Public
Industry Sector: HealthTechnology
CEO: Bobak Azamian, MD, PhD
Number Of Employees: 323
Enterprise Value: $1,863,240,269
PE Ratio: -15.5
Exchange/Ticker 1: NASDAQ:TARS
Exchange/Ticker 2: N/A
Latest Market Cap: $1,845,559,424
BioCentury | Mar 14, 2025
Finance
Insilico, Lila draw nine-figure venture rounds: Finance Report
Plus: public companies Beam, Tarsus and Mineralys raise follow-ons
BioCentury | Nov 6, 2024
Management Tracks
SOBI to propose David Meek as chair
Plus: Seaport hires Lauren White as CFO, and updates from Tarsus and Takeda
BioCentury | Aug 2, 2024
Management Tracks
James Wilson, gene therapy trailblazer, exits Penn to launch two newcos
Plus: Myriad hires Jennifer Fox as chief legal officer, and updates from Odyssey, Enveda and Accelerated Cure Project
BioCentury | Mar 1, 2024
Finance
Public equity report: PIPEs, follow-ons for 11 biotechs add up to $3B+
Viking, Celldex, Janux offerings top list of follow-ons; Denali, Crinetics, Avidity among those raising PIPEs
BioCentury | Feb 28, 2024
Product Development
Clinical report: Early efficacy signals triple Janux’s value; Tarsus reveals tick-killing data
Plus: readouts from Sanofi in hives, GSK in gonorrhea; Shionogi’s digital therapeutic and InDex’s next steps
BioCentury | Jan 5, 2024
Regulation
FDA’s 2023 approvals — a lull in innovation
2023 delivered the second-largest number of FDA new drug approvals ever, yet less innovation in targets, modalities and indications
BioCentury | Oct 31, 2023
Deals
Oct. 31 Quick Takes: Lilly buying Beam’s opt-in rights for Verve base editing programs
Plus: GSK buys Janssen’s rights to Arrowhead HBV product and more from Galapagos, Sarepta, Amgen, LianBio and X4
BioCentury | Oct 25, 2023
Deals
Oct. 24 Quick Takes: BMS buying back Asia rights to mavacamten from LianBio
Plus: Rampart raises $85M series A for DNA-based therapies and updates from Servier, Novartis, Cargo and more
BioCentury | Sep 8, 2023
Data Byte
Follow-on financing activity dips in August
The end of summer slowed biotech follow-on activity, but the companies that did raise money have had relatively strong market performances
BioCentury | Aug 2, 2023
Finance
Aug. 2 Quick Takes: CG Oncology raises $105M crossover round
Plus: Emerson Collective spins out Yosemite with $200M cancer fund, first commercial patient receives Sarepta’s DMD gene therapy, and more
Items per page:
1 - 10 of 26